SenesTech Reports Significant Reductions in Rodent Activity Following Evolve® Deployments in Urban Field Studies
Rhea-AI Summary
SenesTech (NASDAQ: SNES) reported multi-month field results showing marked reductions in rodent activity after Evolve® deployments in two urban locations between April–August 2025 and January 2026. Tracking-plate surveys over five months showed Location A plate presence fell from 74% to 15% (79% reduction) and track density fell 88%. Location B fell from 98% to 47% presence (>50% reduction) with a 71% density decline. Results were measured via standardized tracking plates and reflect real-world urban conditions; Location A lacked pre-deployment baseline data.
Positive
- Location A plate presence down 79% (74% to 15%)
- Location A track density decreased 88% over five months
- Location B plate presence reduced >50% (98% to 47%)
- Location B track density declined 71% in five months
- Five-month field measurement using standardized tracking plates
Negative
- No baseline data available for Location A prior to April 2025
- Limited scope: results from only two urban locations may limit generalizability
- Observational design without randomized control limits causal attribution
News Market Reaction – SNES
On the day this news was published, SNES declined 1.06%, reflecting a mild negative market reaction. Argus tracked a peak move of +8.4% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $137K from the company's valuation, bringing the market cap to $13M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
SNES gained 18%, while peers showed mixed moves (e.g., CNEY +6.06%, BSLK -19.85%, BON -5.23%). With no peers in the momentum scanner and no same-day peer news, the move appears stock-specific, tied to Evolve® field results.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 10 | Channel strategy shift | Positive | -2.7% | Company took direct control of Amazon sales to improve margins and data. |
| Feb 02 | Regulatory approval | Positive | +9.7% | Evolve received approval for use in New Zealand with initial stocking. |
| Jan 28 | CEO transition plan | Negative | -1.0% | CEO retirement plan and leadership transition details were announced. |
| Nov 11 | Distributor expansion | Positive | -8.2% | Belize Raptor Center became official distributor after regulatory approval. |
| Nov 10 | Earnings report | Positive | +2.6% | Record Q3 revenue, strong Evolve growth, improved losses and cash position. |
Positive commercial or regulatory news has not always led to gains; some upbeat Evolve announcements saw negative next-day reactions.
Over the past few months, SenesTech has reported several growth-oriented milestones. On Nov 10, 2025, Q3 2025 revenue reached a record $690,000 with 43% YoY growth and Evolve products at 85% of revenue, yet the stock rose only 2.65%. International expansion continued with a Belize distributor on Nov 11, 2025 and New Zealand approval on Feb 2, 2026 (reaction +9.73%). The Feb 10, 2026 Amazon channel shift drew a -2.7% move. Today’s urban field-study results add real-world efficacy data to this commercialization narrative.
Regulatory & Risk Context
An effective S-3 shelf filed on Aug 15, 2025 registers common shares and warrant-related stock for resale by existing holders. The company would only receive cash upon warrant exercises and has highlighted dilution risk from outstanding warrants and potential exercises subject to ownership limits.
Market Pulse Summary
This announcement highlighted substantial real-world reductions in rodent activity, including plate presence dropping from 98% to 47% at one urban site and track density declines of up to 88%. These data build on prior milestones such as record Q3 2025 revenue of $690,000 and growing Evolve channel expansion. Investors may watch for additional structured studies, new municipal or international deployments, leadership transition execution, and any further use of the existing S-3 registration and warrant structure.
Key Terms
fertility control medical
integrated pest management technical
AI-generated analysis. Not financial advice.
Location A – Deployment Initiated April 2025
In the first monitored area, where Evolve placement began in April 2025, tracking plate data collected from August 2025 through January 2026 showed declines in both rodent presence and activity levels.
- The proportion of plates marked with rodent tracks declined from an average of
74% in August 2025 to15% in January 2026, representing a79% reduction in overall plate presence. - Track density on plates with rodent presence decreased by
88% over the same period.
While baseline data prior to the initial April 2025 product placement were not available, these findings indicate that within five months of monitored observation, rodent activity in the surveyed area declined in both prevalence and intensity.
Location B – Trial Initiated August 2025 with Baseline
In the second monitored area, Evolve deployment commenced immediately following completion of an August 2025 baseline survey, allowing for direct pre- and post-treatment comparison.
- Prior to product placement in August 2025,
98% of tracking plates showed rodent presence. - After five months of baiting, plate presence declined to
47% in January 2026, representing over a50% reduction in overall presence. - Track density declined by
71% during the same period.
These results reflect measurable reductions in rodent activity within five months of Evolve deployment at this location, based on both presence and density indicators.
Study Methodology
Rodent activity was assessed using tracking plates placed throughout each monitored area. Plates were evaluated for the presence of rodent tracks and the relative density of markings. Surveys were conducted at consistent intervals to assess changes over time. Results reflect field observations under real-world urban conditions.
"Results and structured studies such as these are critical as municipalities, pest management professionals and other stakeholders evaluate fertility control as part of broader integrated pest management programs. Objective field data can help inform decisions regarding potential additional deployments and consideration of expansion into new locations," said Joel Fruendt, President and CEO of SenesTech.
"It is a really simple concept. We know from the lab and the field that rats eat the product. We know from the lab that if rats eat our bait, they reproduce less. And we know that rat populations decrease when reproduction decreases," continued Fruendt. "Evolve Rodent Birth Control works!"
About SenesTech, Inc.
SenesTech is committed to creating healthier environments by managing animal pest populations through birth control. The company's groundbreaking products, including Evolve rodent birth control, integrate seamlessly into pest management programs, significantly enhancing their effectiveness while reducing reliance on traditional poisons. SenesTech's mission is to create cleaner cities, more efficient businesses, and healthier communities with products that are effective and sustainable.
For more information, visit https://senestech.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of federal securities laws. Forward-looking statements may include statements regarding the effectiveness of Evolve™ in reducing rodent populations, the potential impact of birth control on long-term rodent management, and the potential impact of the reported results, including on the evaluation of additional deployments and expansion into new locations. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause such differences include, among others, variability in field conditions, implementation practices, market acceptance of our products, regulatory considerations, and other risks described in SenesTech's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them except as required by law.
Investor Contact:
Robert Blum, Lytham Partners, LLC
(602) 889-9700, senestech@lythampartners.com
Company Contact:
Tom Chesterman, SenesTech, Inc.
(928) 233-7533, investors@senestech.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/senestech-reports-significant-reductions-in-rodent-activity-following-evolve-deployments-in-urban-field-studies-302691116.html
SOURCE SenesTech, Inc.
FAQ
What were the reported rodent reductions from SenesTech (SNES) Evolve deployments in January 2026?
How long did SenesTech (SNES) monitor Evolve effects in the urban field studies?
What methods did SenesTech (SNES) use to measure rodent activity in the studies?
Did SenesTech (SNES) have baseline data for both study locations before Evolve deployment?
What do SenesTech’s (SNES) tracking-plate results imply for municipal rodent control decisions?
